Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
36.4M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
36.6M
-
Shares change
-
+94.6K
-
Total reported value, excl. options
-
$649M
-
Value change
-
+$1.21M
-
Number of buys
-
34
-
Number of sells
-
-17
-
Price
-
$17.74
Significant Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value (RAPP) as of Q4 2024
74 filings reported holding RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2024.
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value (RAPP) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.6M shares
.
Largest 10 shareholders include TRV GP V, LLC (7.14M shares), FMR LLC (5.49M shares), ARCH Venture Management, LLC (3.73M shares), Cormorant Asset Management, LP (2.94M shares), Capital International Investors (2.6M shares), JOHNSON & JOHNSON (2.5M shares), Sofinnova Investments, Inc. (2M shares), T. Rowe Price Investment Management, Inc. (1.64M shares), GOLDMAN SACHS GROUP INC (1.25M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.14M shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.